EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: A randomised, double-blind, placebo-controlled phase 2 clinical trial

The Lancet

Volumn 383, Issue 9929, 2014, Pages 1637-1647

  Rice, Andrew S C ^a   Dworkin, Robert H ^b   McCarthy, Tom D ^c   Anand, Praveen ^a   Bountra, Chas ^d   McCloud, Philip I ^e   Hill, Julie ^e   Cutter, Gary ^f,g   Kitson, Geoff ^c   Desem, Nuket ^c   Raff, Milton ^h,i  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c Spinifex Pharmaceuticals   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Narabang Way   (Australia)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g Pythagoras Inc   (United States)

^h Christiaan Barnard Memorial Hospital   (South Africa)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; EMA 401; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; RECEPTOR, ANGIOTENSIN, TYPE 2; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84900307488     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62337-5     Document Type: Article

References (32)

1. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
2. VanAtten MK, Ensinger CL, Chiu AT, et al. A novel series of selective, non-peptide inhibitors of angiotensin II binding to the AT2 site. J Med Chem 1993; 36: 3985-92.
3. Anand U, Facer P, Yiangou Y, et al. Angiotensin II type 2 receptor (AT2 R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain 2013; 17: 1012-26.
4. Smith MT, Woodruff TM, Wyse BD, et al. A small molecule angiotensin II type 2 receptor (AT2 R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia. Pain Med 2013; 14: 1557-68.
5. Smith MT, Wyse BD, Edwards SR. Small molecule angiotensin II type 2 receptor (AT R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med 2013; 14: 692-705.
6. Smith MT, Lau T, Wallace VCJ, Wyse BD, Rice ASC. Analgesic efficacy of small molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy (ATN). Behav Pharmacol (in press).
7. Chakrabarty A, Liao Z, Smith PG. Angiotensin II receptor type 2 activation is required for cutaneous sensory hyperinnervation and hypersensitivity in a rat hind paw model of inflammatory pain. J Pain 2013; 14: 1053-65.
8. Jensen TS, Baron R, Haanp M, et al. A new definition of neuropathic pain. Pain 2011; 152: 2204-05.
9. Scott FT, Leedham-Green ME, Barrett-Muir WY, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70 (suppl 1): S24-30.
10. Gauthier A, Breuer J, Carrington D, Martin M, Ry V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009; 137: 38-47.
11. Daniel HC, Narewska J, Serpell M, Hoggart B, Johnson R, Rice AS. Comparison of psychological and physical function in neuropathic pain and nociceptive pain: implications for cognitive behavioral pain management programs. Eur J Pain 2008; 12: 731-41.
12. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27: 1454-67.
13. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150: 573-81.
14. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern R, Rice ASC. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005; 2: 628-44.
15. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain 2010; 150: 12-16.
16. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 2012; 153: 1148-58.
17. Atkinson TM, Mendoza TR, Sit L, et al. The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. Pain Med 2010; 11: 337-46.
18. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004; 20: 309-18.
19. Bastien CH, Vallies A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001; 2: 297-307.
20. Dworkin RH, Turk DC, Revicki DA, et al. Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain 2009; 144: 35-42.
21. Pincus T, Williams AC, Vogel S, Field A. The development and testing of the depression, anxiety, and positive outlook scale (DAPOS). Pain 2004; 109: 181-88.
22. Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O'Neill E. Factor structure, reliability, and validity of the Pain Catastrophizing Scale. J Behav Med 1997; 20: 589-605.
23. Moore RA, Straube S, Eccleston C, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012; 153: 265-68.
24. Sang CN, Sathyanarayana R, Sweeney M, and the DM-1796 Study Investigators. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clin J Pain 2013; 29: 281-88.
25. Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. J Pain Symptom Manage 2006; 31: 369-77.
26. Steckelings UM, Unger T. Angiotensin II type 2 receptor agonists - where should they be applied? Expert Opin Investig Drugs 2012; 21: 763-66.
27. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, and the Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-12.
28. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013; 346: f2690.
29. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; 10: CD009183.
30. Derry S, Rice ASC, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2013; 2: CD007393.
31. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev 2013; 11: CD010567.
32. Brillante DG, O'Sullivan AJ, Johnstone MT, Howes LG. Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance. Diabetes Obes Metab 2008; 10: 143-50.